Pharmacotherapy for Obese Adolescents

Pediatric Clinics of North America

Volumn 58, Issue 1, 2011, Pages 139-153

  Greydanus, Donald E ^a   Bricker, Lee A ^a,b   Feucht, Cynthia ^c,d  

^a MICHIGAN STATE UNIVERSITY   (United States)

^b Michigan State University Kalamazoo Center for Medical Studies   (United States)

^c Borgess Ambulatory Care   (United States)

^d FERRIS STATE UNIVERSITY   (United States)

Author keywords

Adolescents; Obesity; Pharmacotherapy

Indexed keywords

ACARBOSE; AMFEBUTAMONE; AMFEPRAMONE; AMPHETAMINE; BENZPHETAMINE; CILIARY NEUROTROPHIC FACTOR; DEXFENFLURAMINE; EPHEDRA SINICA EXTRACT; EXENDIN 4; FENFLURAMINE; FLUOXETINE; INCRETIN; LEPTIN; LONAMIN; METFORMIN; OXYNTOMODULIN; PEPTIDE YY; PHENDIMETRAZINE; PHENTERMINE; PHENYLPROPANOLAMINE; PLACEBO; PRAMLINTIDE; RIMONABANT; SAXAGLIPTIN; SERTRALINE; SIBUTRAMINE; SITAGLIPTIN; TETRAHYDROLIPSTATIN; TOPIRAMATE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VILDAGLIPTIN;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ADOLESCENT HEALTH; ANXIETY; ASTHENIA; BODY MASS; CONSTIPATION; CONTINUOUS INFUSION; DEFECATION URGENCY; DEPRESSION; DIABETES MELLITUS; DIARRHEA; DIET SUPPLEMENTATION; DIZZINESS; DOSE RESPONSE; DRUG APPROVAL; DRUG CONTRAINDICATION; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; DYSPEPSIA; EATING HABIT; ECHOCARDIOGRAPHY; EPHEDRA SINICA; FECES INCONTINENCE; FLATULENCE; FOOD AND DRUG ADMINISTRATION; FOOD INTAKE; GASTROINTESTINAL SYMPTOM; HEADACHE; HORMONE ACTION; HORMONE BLOOD LEVEL; HUMAN; HYPERTENSION; HYPOTHALAMUS FUNCTION; INDIGESTION; INJECTION SITE IRRITATION; INSOMNIA; KINESIOTHERAPY; LACTIC ACIDOSIS; MALABSORPTION; METABOLIC SYNDROME X; MORBID OBESITY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OVARY POLYCYSTIC DISEASE; PULMONARY HYPERTENSION; PULSE RATE; RESTLESSNESS; REVIEW; SIDE EFFECT; SOMNOLENCE; STEATORRHEA; TOBACCO DEPENDENCE; UNSPECIFIED SIDE EFFECT; VALVULAR HEART DISEASE; VOMITING; WEIGHT REDUCTION; XEROSTOMIA;

ADOLESCENT; AMPHETAMINES; ANTI-OBESITY AGENTS; ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS; CENTRAL NERVOUS SYSTEM STIMULANTS; CILIARY NEUROTROPHIC FACTOR; HERBAL MEDICINE; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; OBESITY; PIPERIDINES; PYRAZOLES;

EID: 79251588069     PISSN: 00313955     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pcl.2010.10.007     Document Type: Review

References (96)

1. Reddy V. Obesity. Behavioral pediatrics 2009, 405-415. Nova Science Publishers, New York, chapter 24. 3rd edition. D.E. Greydanus, D.R. Patel, H.D. Pratt (Eds.).
2. Yanovski S.Z., Yanovski J.A. Obesity. N Engl J Med 2002, 346(8):591-602.
3. Kirk S., Scott B.J., Daniels S.R. Pediatric obesity epidemic: treatment options. J Am Diet Assoc 2005, 105(5 Suppl 1):S44-S51.
4. Godoy-Matos A., Carraro L., Vieira A., et al. Treatment of obese adolescents with sibutramine: a randomized, double-blind, controlled study. J Clin Endocrinol Metab 2005, 90:1460-1465.
5. Rowlett J.R. Obesity in the adolescent. Essential adolescent medicine 2006, 651-665. McGraw-Hill Medical Publishers, New York, chapter 31. D.E. Greydanus, D.R. Patel, H.D. Pratt (Eds.).
6. Barlow SE and the Expert Committee Expert committee recommendations regarding prevention, assessment, and treatment of child and adolescent overweight and obesity: summary report. Pediatrics 2007, 120(Suppl 4):S164-S192.
7. Skelton J.A., Rudolph C.D. Overweight and obesity. Nelson textbook of pediatrics 2007, 232-242. Saunders/Elsevier, Philadelphia, chapter 44. 18th edition. R.M. Kliegman, R.E. Behrman, H.B. Jenson (Eds.).
8. Eneli I., Davies H.D. Epidemiology of childhood obesity. Obesity in childhood and adolescence 2008, vol. 1:3-23. Praeger Publishers, Westport (CT), chapter 1. H.D. Davies (Ed.).
9. Jones K.L. Role of obesity in complicating and confusing the diagnosis and treatment of diabetes in children. Pediatrics 2008, 121(2):361-368.
10. Kiess W., Boettner A. Obesity in the adolescent. Adolesc Med 2002, 13:181-190.
11. Atkinson R.L., Hubbard V.S. Report on the NIH Workshop on Pharmacologic Treatment of Obesity. Am J Clin Nutr 1994, 60(2):153.
12. Bray G.A., Tartaglia L. Medicinal strategies in the treatment of obesity. Nature 2000, 404:672-677.
13. Jensen M.D. Medical management of obesity. Semin Gastrointest Dis 1998, 9:156-162.
14. Freemark M., Kiess W. Anti-obesity medication use in adolescents: risks and benefits. Pediatr Endocrinol Rev 2004, 2(Suppl 1):168-170.
15. McDuffie J.R., Calis K.A., Uwaifo G.I., et al. Efficacy of orlistat as an adjunct to behavioral treatment in overweight African American and Caucasian adolescents with obesity-related co-morbid conditions. J Pediatr Endocrinol Metab 2004, 17:307-319.
16. Molnar D. New drug policy in childhood obesity. Int J Obes (Lond) 2005, 29(Suppl 2):S62-S65.
17. Snow V., Barry P., Fitterman N., et al. Pharmacologic and surgical management of obesity in primary care: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2005, 142:525-531.
18. Joffe A. Pharmacotherapy for adolescent obesity: a weighty issue. JAMA 2005, 293:2932-2934.
19. Lean M., Finer N. ABC of obesity. Management: part II-drugs. BMJ 2006, 333:794-797.
20. Dunican K.C., Desilets A.R., Montalbano J.K. Pharmacotherapeutic options for overweight adolescents. Ann Pharmacother 2007, 41:1445-1455.
21. Eneli I., Mantinan K.D. Managing the overweight child. Obesity in childhood and adolescence 2008, vol. 2:191-225. Praeger Publishers, Westport (CT), chapter 9. H.E. Fitzgerald, V. Mousouli (Eds.).
22. Hofmann A.D. Obesity. Adolescent medicine 1997, 663-682. Appleton & Lange, Stamford (CT), chapter 30. 3rd edition. A.D. Hofmann, D.E. Greydanus (Eds.).
23. Greydanus D.E., Bricker L.A., Patel D.R. The benefits of sports participation in childhood and adolescence to prevent obesity in adolescents and adults. Asian J Paediatric Practice 2006, 9(4):1-7.
24. Greydanus D.E., Bhave S. Obesity in the adolescent. Indian Pediatr 2004, 41(6):545-550.
25. Chanoine J.P., Hampl S., Jensen C., et al. Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. JAMA 2005, 293:2873-2883.
26. Berkowitz R.I., Wadden T.A., Tershakovec, et al. Behavioral therapy and sibutramine for the treatment of adolescent obesity. A randomized controlled trial. JAMA 2003, 289:1805-1812.
27. Berkowitz R.I., Fujioka K., Daniels S.R., et al. Effects of sibutramine treatment in obese adolescents: a randomized trial. Ann Intern Med 2006, 145:81-90.
28. Reisler G., Tauber T., Afriat R., et al. Sibutramine as an adjuvant therapy in adolescents suffering from morbid obesity. Isr Med Assoc J 2006, 8:30-32.
29. Webb E., Viner R. Should metformin be prescribed to overweight adolescents in whom dietary/behavioural modifications have not helped?. Arch Dis Child 2006, 91:793-794.
30. Silverstone T. Appetite suppressants. A review. Drugs 1992, 43(6):820.
31. US Food and Drug Administration [homepage on the Internet] [cited 2008 March 6]. Food and Drug Administration Science Background Safety of Phenylpropanolamine; [about 2 Screens]. Available at:, Accessed November 15, 2010. http://www.fda.gov.cder/drug/infopage/ppa/science.htm.
32. Yoo J.H., Lee E.J., Kwak C.K., et al. Clinical trial of herbal formula on weight loss in obese Korean children. Am J Chin Med 2005, 33:713-722.
33. Seamon M., Clauson K. Ephedra: yesterday, DSHEA, and tomorrow-a ten year perspective on the dietary supplement health and education act of 1994. J Herb Pharmacother 2005, 5:67-86.
34. Greydanus D.E., Patel D.R. Sports doping in the adolescent athlete: the hope, hype, and hyperbole. Pediatr Clin North Am 2002, 49:829-855.
35. US Food and Drug Administration [homepage on the Internet] [cited 2008 March 6]. FDA Announces Withdrawal Fenfluramine and Dexfenfluramine (Fen-Phen); [about 2 Screens]. Available at:, Accessed November 20, 2010. http://www.fda.gov/cder/news/phen/fenphenpr81597.htm.
36. Sibutramine for obesity. Med Lett Drugs Ther 1998, 40:32.
37. Early J.L., Apovian C.M., Aronne L.J., et al. Sibutramine plus meal replacement therapy for body weight loss and maintenance in obese patients. Obesity (Silver Spring) 2007, 15:1464-1472.
38. Violante-Ortiz R., Rel-Rio-Navarro B.E., Lara-Esqueda A., et al. Use of sibutramine in obese Hispanic adolescents. Adv Ther 2005, 22:642-649.
39. Garcia-Morales L.M., Berber A., Macias-Lara C.C., et al. Use of sibutramine in obese Mexican adolescents: a 6 month, randomized, double-blind, placebo- controlled, parallel-group trial. Clin Ther 2006, 28:770-782.
40. Daniels S.R., Long B., Crow S., et al. Cardiovascular effects of sibutramine in the treatment of obese adolescents: results of a randomized, double-blind, placebo-controlled study. Pediatrics 2007, 120:e147-e157.
41. Doggrell S.A. Sibutramine for obesity in adolescents. Expert Opin Pharmacother 2006, 7:2435-2438.
42. Danielsson P., Janson A., Norgren S., et al. Impact sibutramine therapy in children with hypothalamic obesity or obesity with aggravating syndromes. J Clin Endocrinol Metab 2007, 92:4101-4106.
43. Davidson M.H., Hauptman J., DiGirolamo M., et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized trial. JAMA 1999, 281:235-242.
44. Orlistat OTC for weight loss. Med Lett Drugs Ther 2007, 49:49.
45. Orlistat for obesity. Med Lett Drugs Ther 1999, 41:55.
46. Anderson J.W. Low-dose orlistat effects on body weight of mildly to moderately overweight individuals: a 16 week, double-blind, placebo-controlled trial. Ann Pharmacother 2006, 40:1717.
47. Maahs D., de Serna D.G., Kolotkin R.L., et al. Randomized, double-blind, placebo-controlled trial of orlistat for weight loss in adolescents. Endocr Pract 2006, 12:18-28.
48. Ozkan B., Bereket A., Turan S., et al. Addition of orlistat to conventional treatment in adolescents with severe obesity. Eur J Pediatr 2004, 163(12):738-741.
49. Nestler J.E. Metformin for the treatment of polycystic ovary syndrome. N Engl J Med 2008, 358(1):47-54.
50. Hoppin A.G., Katz E.S., Kaplan L.M., et al. Case 31-2006: a 15-year-old girl with severe obesity. N Engl J Med 2006, 355(15):1593-1602.
51. Harborne L., Fleming R., Lyall H., et al. Metformin or antiandrogen in the treatment of hirsutism in polycystic ovary syndrome. J Clin Endocrinol Metab 2003, 88:4116-4123.
52. Freemark M. Pharmacotherapy of childhood obesity: an evidence-based, conceptual approach. Diabetes Care 2007, 30:395-402.
53. Srinivasan S., Ambler G.R., Baur L.A., et al. Randomized, controlled trial of metformin for obesity and insulin resistance in children and adolescents: improvement in body composition and fasting insulin. J Clin Endocrinol Metab 2006, 91(6):2074-2080.
54. Pagotto U., Pasquali R. Fighting obesity and associated risk factors by antagonizing cannabinoid type 1 receptors. Lancet 2005, 365:1363-1364.
55. Pi-Sunyer F.X., Arrone L.J., Heshmati H.M., et al. Effect of rimonabant, a cannabinoid-1-receptor blocker on weight and cardiometabolic risk factors in overweight or obese patients. JAMA 2006, 295:761-775.
56. Huestis M.A., Gorelick D.A., Heishman S.J., et al. Blockage of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716. Arch Gen Psychiatry 2001, 58(4):322-328.
57. Maldonado R., Valverde O., Berrendero F. Involvement of the endocannabinoid system in drug addiction. Trends Neurosci 2006, 29(4):225-232.
58. US Food and Drug Administration [homepage on the Internet] [cited 2008 March 6]. FDA Briefing Document; NDA 21-888 (rimonabant); [about 84 screens]. Available at:. http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4306b1-fda-backgrounder.pdf.
59. Fluoxetine (Prozac) and other drugs for treatment of obesity. Med Lett Drugs Ther 1994, 36(936):107.
60. Greydanus D.E., Calles J., Patel D.R. Pediatric and adolescent psychopharmacology: a primer for the pediatrician 2008, Cambridge University Press, Cambridge (UK), p. 300.
61. Bray G.A., Hollander P., Klein S., et al. A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity. Obes Res 2003, 11(6):722-733.
62. McElroy S.L., Guerdjikova A.I., Martens B., et al. Role of antiepileptic drugs in the management of eating disorders. CNS Drugs 2009, 23(2):139-156.
63. Bongioanni P., Reali C., Sogos V. Ciliary neurotrophic factor (CNTF) for amyotrophic lateral sclerosis or motor neuron disease. Cochrane Database Syst Rev 2004, (3):CD004302.
64. Matthews V.B., Febbraio M.A. CNTF: a target therapeutic for obesity-related metabolic disease?. J Mol Med 2008, 86(4):353-361.
65. Gloaguen I., Costa P., Demartis A., et al. Ciliary neurotrophic factor corrects obesity and diabetes associated with leptin deficiency and resistance. Proc Natl Acad Sci U S A 1997, 94(12):6456-6461.
66. Kokoeva M.V., Yin H., Flier J.S. Neurogenesis in the hypothalamus of adult mice: potential role in energy balance. Science 2005, 310(5748):679-683.
67. Suzuki K., Simpson K.A., Minnion J.S., et al. The role of gut hormones and the hypothalamus in appetite regulation. Endocr J 2010, 57(5):359-372.
68. Roth C.L., Reinehr T. Roles of gastrointestinal and adipose tissue peptides in childhood obesity and changes after weight loss due to lifestyle intervention. Arch Pediatr Adolesc Med 2010, 164(2):131-138.
69. Considine R.V., Sinha M.K., Heiman M.L., et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 1996, 334:292-295.
70. Montague C.T., Farooqi I.S., Whitehead J.P., et al. Congenital leptin deficiency is associated with severe early-onset obesity in humans. Nature 1997, 387(6636):903-908.
71. Farooqi I.S., Matarese G., Lord G.M., et al. Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency. J Clin Invest 2002, 110:1093-1103.
72. Heymsfield S.B., Greenberg A.S., Fujioka K., et al. Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose escalation trial. JAMA 2000, 283:1567-1568.
73. Ahima R.S., Flier J.S. Leptin. Annu Rev Physiol 2000, 62:413-437.
74. Fineman M.S., Koda J.E., Shen L.Z., et al. The human amylin analog, pramlintide, corrects postprandial hyperglucagonemia in patients with type 1 diabetes. Metabolism 2002, 51:636-641.
75. Hirsch I.B., Blonde L., Buse J., et al. Consensus development conference on pramlintide in the management of type 1 and type 2 diabetes 2006, The Diabetes Education Group, Lakeville (CT).
76. Dunican K.C., Adams N.M., Desilets A.R. The role of pramlintide for weight loss. Ann Pharmacother 2010, 44(3):538-545.
77. Ravussin E., Smith S.R., Mitchell J.A., et al. Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy. Obesity (Silver Spring) 2009, 17(9):1736-1743.
78. Parkes D.G., Pittner R., Jodka C., et al. Insulinotropic actions of exendin-4 and glucagon-like peptide 1 in vivo and in vitro. Metabolism 2001, 50:583-589.
79. Riddle M.C., Henry R.R., Poon T.H., et al. Exenatide elicits sustained glycaemic control and progressive reduction of body weight in patients with type 2 diabetes inadequately controlled by sulphonylureas with or without metformin. Diabetes Metab Res Rev 2006, 22(6):483-491.
80. Nauck M.A., Kleine N., Orskov C., et al. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1993, 36:741-774.
81. Raman V.S., Mason K.J., Rodriguez L.M., et al. The role of adjunctive exenatide therapy in pediatric type 1 diabetes. Diabetes Care 2010, 33(6):1294-1296.
82. Colagiuri S. Diabesity: therapeutic options. Diabetes Obes Metab 2010, 12(6):463-473.
83. Niswender K. Diabetes and obesity: therapeutic targeting and risk reduction - a complex interplay. Diabetes Obes Metab 2010, 12(4):267-287.
84. Wynne K., Park A.J., Small C.J., et al. Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: a double-blind, randomized, controlled trial. Diabetes 2005, 54(8):2390-2395.
85. Batterham R.L., Bloom S.R. The gut hormone peptide YY regulates appetite. Ann N Y Acad Sci 2003, 994:162-168.
86. Gantz I., Erondu N., Mallick M., et al. Efficacy and safety of intranasal peptide YY3-36 for weight reduction in obese adults. J Clin Endocrinol Metab 2007, 92(5):1754-1757.
87. Misra M., Miller K.K., Tsai P., et al. Elevated peptide YY levels in adolescent girls with anorexia nervosa. J Clin Endocrinol Metab 2006, 91(3):1027-1033.
88. Ueno H., Shiiya T., Nakazato M. Translational research of ghrelin. Ann N Y Acad Sci 2010, 1200:120-127.
89. Inui A., Asakawa A., Bowers C.Y., et al. Ghrelin, appetite, and gastric motility: the emerging role of the stomach as an endocrine organ. FASEB J 2004, 18(3):439-456.
90. Zhang J.V., Ren P.G., Avsian-Kretchmer O., et al. Obestatin, a peptide encoded by the ghrelin gene, opposes ghrelin's effects on food intake. Science 2005, 310(5750):996-999.
91. Hassouna R., Zizzari P., Tolle V. The ghrelin/obestatin balance in the physiological and pathological control of GH secretion, body composition and food intake. J Neuroendocrinol 2010, 22:793-804.
92. Verhagen L.A., Egecioglu E., Luijendijk M.C., et al. Acute and chronic suppression of the central ghrelin signaling system reveals a role in food anticipatory activity. Eur Neuropsychopharmacol 2010, 20. [Epub ahead of print].
93. Germain N., Galusca B., Grouselle D., et al. Ghrelin and obestatin circadian levels differentiate bingeing-purging from restrictive anorexia nervosa. J Clin Endocrinol Metab 2010, 95(6):3057-3062.
94. Ashitani J., Matsumoto N., Nakazato M. Ghrelin and its therapeutic potential for cachectic patients. Peptides 2009, 30(10):1951-1956.
95. Field B.C., Wren A.M., Peters V., et al. PYY3-36 and oxyntomodulin can be additive in their effect on food intake in overweight and obese humans. Diabetes 2010, 59(7):1635-1639.
96. Nandagopal R., Brown R.J., Rother K.I. Resolution of type 2 diabetes following bariatric surgery: implications for adults and adolescents. Diabetes Technol Ther 2010, 12(8):671-677.